Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.

Eytan Ben-AmiConstance M BarysauskasSarah SolomonKadija TahlilRita MalleyMelissa HohosKathleen PolsonMargaret LoucksMariano SevergniniTara PatelAmy CunninghamScott J RodigF Stephen HodiJeffrey A MorganPriscilla MerriamAndrew J WagnerGeoffrey I ShapiroSuzanne George

Published in: Cancer (2017)

Single-agent nivolumab did not demonstrate a benefit in this cohort of previously treated advanced ULMS patients. Further biomarker-driven approaches and studies evaluating combined immune checkpoint-modulators should be considered. Cancer 2017;123:3285-90. © 2017 American Cancer Society.

Keyphrases

papillary thyroid
end stage renal disease
newly diagnosed
squamous cell
ejection fraction
chronic kidney disease
small molecule
prognostic factors
peritoneal dialysis
squamous cell carcinoma
clinical trial